Our Fisher Clinical ServicesSM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Please update your bookmark.
독물학자의 관점에서의 항암제 개발
항암제 분야가 성장하면서 제약회사는 빠르고 민첩하게 생명을 구하는 치료제를 개발하고 생산해야 한다는 압박을 받고 있습니다. 항암제 시장 파이프라인의 약 42%를 경구제*가 차지하고 있으며 항암제는 일반적으로 고효능 의약품으로 분류되기 때문에 다양한 취급 및 안전 전략이 필요합니다. 이 웨비나에서 다음 주제에 대한 독물학자 Joe Galati의 설명을 들을 수 있습니다.
고활성 저분자 평가 기준
독성 결합 시스템
고활성에서 저활성으로 분자 다운그레이드
안전 및 취급 전략
*출처: IQVIA- Global MIDAS Edition Includes antineoplastic agents (L01) and endocrine therapy (L02)- 248 molecules, OSD includes: tablets, ODT, capsules
Joe Galati Thermo Fisher Scientific Global Toxicology Services 선임 이사(SD)
Bio: Dr. Joe Galati is the Senior Director of Global Toxicology Services and has 20 years of experience in the pharmaceutical industry, in the field of occupational toxicology and patient/product safety. Involved in evaluating the toxicity of compounds (active pharmaceutical ingredients, intermediates, contaminants, etc.) in order to assign appropriate toxicity categorizations/bands, determine low potency versus high potency, and develop occupational exposure limits for worker safety, as well as threshold of toxicological concern/permitted daily exposure/acceptable daily exposure values for patient safety. Also involved in identifying whether the handling of compounds complies with the requirements for Good Manufacturing Practice in a multi-product facility and advising on potential drug product quality/regulatory concerns, such as cytotoxic, cytostatic, hormone, sensitizer, and others. A full member of the U.S. Society of Toxicology, as well as the Society of Toxicology of Canada, with a Ph.D. in Pharmacology and Molecular Toxicology from the University of Toronto. Also, an author of several peer-reviewed publications, and a presenter at various international scientific meetings, conferences, and universities, in North America and Europe.